Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (581-590 of 666) with videos related to

Pageof 67
Sort By:
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 28, 2015
Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year periodMoniek W M van de Luijtgaarden, Kitty J Jager, Mårten Segelmark, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 17, 2020
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus WorkshopEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Kidney International|April 5, 2003
Review on uremic toxins: classification, concentration, and interindividual variabilityRaymond Vanholder, Rita De Smet, Griet Glorieux, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
Pageof 67

Showing results (581-590 of 666) with videos related to

Sort By:
Pageof 67
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 28, 2015
Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year periodMoniek W M van de Luijtgaarden, Kitty J Jager, Mårten Segelmark, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 17, 2020
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus WorkshopEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Kidney International|April 5, 2003
Review on uremic toxins: classification, concentration, and interindividual variabilityRaymond Vanholder, Rita De Smet, Griet Glorieux, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
Pageof 67